# DoD Expands GLP-1 Drug Orders

U.S. Department of Defense-related GLP-1 purchasing reached 26,252 orders totaling **$235.2 million** from January through September 2025, exceeding the full-year 2024 dollar total by 27%. Obesity-only brands accounted for 40% of brand-named orders. Since January 2024, 98.4% of reported federal GLP-1 orders—53,038 of 53,923, valued at $416.4 million—were routed through AmerisourceBergen Drug Corp., now Cencora. The figures indicate substantial military pharmacy demand and concentration in one distributor; they describe purchasing activity, not an announced solicitation, and DoD reporting lags by roughly three quarters.

- Procurement teams can use the reported order volumes and distributor concentration as inputs to pharmaceutical demand planning and supply-chain resilience reviews.
- Cencora’s dominant share makes its role in military pharmacy resupply material to contractors and distributors assessing market access or potential supply-chain dependencies; the data do not establish a new competition or award opportunity.
- The reporting lag means these figures are a historical demand signal rather than a real-time measure of current purchasing.

**Jurisdictions:** federal
**Industries:** Healthcare
**Published:** October 15, 2026

### Government Entities
- U.S. Department of Defense (DoD)

### Vendors
- AmerisourceBergen Drug Corp. (now Cencora) (Pharmaceutical prime vendor and distributor for military pharmacy resupply)
- Dakota Drug (Distributor of federal GLP-1 orders)
- DMS Pharmaceutical Group (Distributor of federal GLP-1 orders)

### Sources
- [US military pharmacies ordered GLP-1 drugs 26,252 times in the first nine months of 2025 - every pen, vial, and tablet bottle a separate line in the federal procurement record. https://t.co/6HMT08iajc #pharma #altdata](https://x.com/ValanTechnology/status/2110694685551255596) - twitter-fed-procurement